PROBLEM TO BE SOLVED: To provide a pharmaceutical composition for oral administration for the treatment of a primary central nervous system tumor involving a novel ROS 1 tyrosine kinase or for the treatment of a cancer involving ROS 1 tyrosine kinase, the cancer being metastasized to the central nervous system.SOLUTION: According to the present invention, there is provided an aromatic heterocyclic derivative represented by the formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof. (Rrepresents phenyl substituted/unsubstituted with one or two groups selected from halogen, halogen substituted/unsubstituted alkyl and alkoxy； Ris H, substituted or unsubstituted alkyl with halogen, cycloalkyl, alkoxy, or heteroaryl substituted/unsubstituted with alkyl； and X is CR, Y is N or CRor X is N is Y is CR； and Z is CRor N)SELECTED DRAWING: None【課題】新規なＲＯＳ１チロシンキナーゼが関与する原発性中枢神経系腫瘍又はＲＯＳ１チロシンキナーゼが関与する中枢神経系に転移したがんの治療のための経口投与用医薬組成物の提供。【解決手段】式［１］で表される芳香族複素環誘導体若しくはその医薬上許容される塩、又はその溶媒和物。（Ｒ１はハロゲン、ハロゲンで置換／未置換のアルキル及びアルコキシから選択される１個又は２個の基で置換／未置換のフェニル；Ｒ２はＨ、ハロゲンで置換／未置換のアルキル、シクロアルキル、アルコキシ、又は、アルキルで置換／未置換のヘテロアリール；ＸはＣＲ３をＹはＮ若しくはＣＲ４又は、ＸはＮをＹはＣＲ４；ＺはＣＲ５又はＮ）【選択図】なし
